Annals of Thoracic Medicine
ORIGINAL ARTICLE
Year
: 2013  |  Volume : 8  |  Issue : 2  |  Page : 109--115

Concomitant chemoradiotherapy with docetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unresectable non-small cell lung cancer


Celalettin Eroglu1, Okan Orhan1, Dilek Unal1, Gamze G Dogu2, Halit Karaca2, Mustafa Dikilitas2, Ahmet Oztürk3, Metin Ozkan2, Bünyamin Kaplan1 
1 Department of Radiation Oncology, Erciyes University, School of Medicine, Kayseri, Turkey
2 Department of Medical Oncology, Erciyes University, School of Medicine, Kayseri, Turkey
3 Department of Biostatistics and Medical Informatics, Erciyes University, School of Medicine, Kayseri, Turkey

Correspondence Address:
Celalettin Eroglu
Department of Radiation Oncology, Erciyes University, School of Medicine, M.K. Dedeman Oncology Hospital, 38039 Kayseri
Turkey

Objectives: To evaluate treatment results and toxicities in patients who received concomitant chemoradiotherapy (CRT) followed by consolidation with docetaxel and cisplatin in locally advanced unresectable non-small cell lung cancer (NSCLC). Methods: Ninety three patients were included in this retrospective study. The patients received 66 Gy radiotherapy and weekly 20 mg/m 2 docetaxel and 20 mg/m 2 cisplatin chemotherapy concomitantly. One month later than the end of CRT, consolidation chemotherapy with four cycles of docetaxel 75 mg/m 2 and cisplatin 75 mg/m 2 were administered at each 21 days. Results: Median age of the patients was 57 (range, 30-74). Following concomitant CRT, 14 patients (15%) showed complete and 50 patients (54%) showed partial response (total response rate was 69%). The median follow-up was 13 months (range: 2-51 months). The median overall survival was 18 months (95% confidential interval [CI]: 13.8-22.1 months); local control was 15 months (95% CI: 9.3-20.6 months); progression-free survival was 9 months (95% CI: 6.5-11.4 months). Esophagitis in eight (9%) patients, neutropenia in seven (8%) patients and pneumonitis in eight (9%) patients developed as grade III-IV toxicity due to concomitant CRT. Conclusion: Concomitant CRT with docetaxel and cisplatin followed by docetaxel and cisplatin consolidation chemotherapy might be considered as a feasible, and well tolerated treatment modality with high response rates despite the fact that it has not a survival advantage in patients with locally advanced unresectable NSCLC.


How to cite this article:
Eroglu C, Orhan O, Unal D, Dogu GG, Karaca H, Dikilitas M, Oztürk A, Ozkan M, Kaplan B. Concomitant chemoradiotherapy with docetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unresectable non-small cell lung cancer.Ann Thorac Med 2013;8:109-115


How to cite this URL:
Eroglu C, Orhan O, Unal D, Dogu GG, Karaca H, Dikilitas M, Oztürk A, Ozkan M, Kaplan B. Concomitant chemoradiotherapy with docetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unresectable non-small cell lung cancer. Ann Thorac Med [serial online] 2013 [cited 2021 Dec 3 ];8:109-115
Available from: https://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2013;volume=8;issue=2;spage=109;epage=115;aulast=Eroglu;type=0